Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | ACP1 | P24666 | 2/20 | 0.32 |
| ▸ | CDC25B | P30305 | 2/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.32 |
| ▸ | ESR1 | P03372 | 3/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13548786 | 0.70 | LMNA (0.42) | MAPTLMNAGAASMN1; SMN2PTPN1 | |
| SCHEMBL2803500 | 0.70 | PTPN1 (0.46) | MAPTLMNAGAAPTPN1ALDH1A1 | |
| SCHEMBL435198 | 0.64 | SIRT1 (0.71) | MAPTLMNAGAASMN1; SMN2ALDH1A1 | |
| SCHEMBL9190067 | 0.62 | PTPN1 (0.46) | LMNASMN1; SMN2PTPN1ALDH1A1MAPK1 | |
| SCHEMBL13885529 | 0.61 | ALDH1A1 (0.46) | MAPTLMNAPTPN1ALDH1A1CYP1A2 | |
| SCHEMBL1334195 | 0.61 | MGLL (0.57) | MAPTLMNAKMT2AESR2ESR1 | |
| SCHEMBL5370523 | 0.61 | MGLL (0.57) | MAPTLMNAKMT2AESR2ESR1 | |
| SCHEMBL5370517 | 0.61 | MGLL (0.57) | MAPTLMNAKMT2AESR2ESR1 | |
| SCHEMBL70825 | 0.60 | PTPN1 (0.56) | MAPTLMNAGAASMN1; SMN2PTPN1 | |
| SCHEMBL2472619 | 0.59 | MAPT (0.57) | MAPTLMNAGAASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2595952-B1 | AGONISTS OF GPR40 | CONNEXIOS LIFE SCIENCES PVT LTD (IN) | 2020-11-18 | — | — | EP | disclosed |
| US-9290603-B2 | Amines having secondary aliphatic amino groups | SIKA TECHNOLOGY AG (CH) | 2016-03-22 | — | — | US | disclosed |
| US-9278915-B2 | Agonists of GPR40 | CONNEXIOS LIFE SCIENCES PVT LTD (IN) | 2016-03-08 | — | — | US | disclosed |
| US-20130237681-A1 | AMINES HAVING SECONDARY ALIPHATIC AMINO GROUPS | SIKA TECHNOLOGY AG (CH) | 2013-09-12 | — | — | US | disclosed |
| US-20130237571-A1 | AGONISTS OF GPR40 | Conexios Life Sciences PVT. LTD. (IN) | 2013-09-12 | — | — | US | disclosed |
| EP-2595952-A1 | AGONISTS OF GPR40 | Connexios Life Sciences Pvt. Ltd. (IN) | 2013-05-29 | — | — | EP | disclosed |
| WO-2012011125-A1 | AGONISTS OF GPR40 | CONNEXIOS LIFE SCIENCES PVT. LTD. (IN) | 2012-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130237571-A1 | AGONISTS OF GPR40 | GPR65, GPR55, GPR68 | MAPT 2792/4885LMNA 3516/4885GAA 1970/4885 |
| US-20130237681-A1 | AMINES HAVING SECONDARY ALIPHATIC AMINO GROUPS | AAAS, PNMT, PARG | MAPT 1595/4885LMNA 1183/4885GAA 3277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.